175.50
-0.50
(-0.28%)
At close: 1:30:09 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
844,861.00
758,391.00
627,512.00
438,841.00
70,597.00
Cost of Revenue
253,377.00
273,637.00
212,955.00
193,361.00
88,542.00
Gross Profit
591,484.00
484,754.00
414,557.00
245,480.00
-17,945.00
Operating Expense
167,549.00
147,022.00
130,762.00
129,278.00
139,161.00
Operating Income
423,935.00
337,732.00
283,795.00
116,202.00
-157,106.00
Net Non Operating Interest Income Expense
9,212.00
13,977.00
9,365.00
2,259.00
2,868.00
Pretax Income
334,817.00
623,014.00
264,103.00
396,821.00
-137,398.00
Tax Provision
80,487.00
83,617.00
63,389.00
27,220.00
-30,569.00
Net Income Common Stockholders
254,330.00
539,397.00
200,714.00
369,601.00
-106,829.00
Diluted NI Available to Com Stockholders
254,330.00
539,397.00
200,714.00
369,601.00
-106,829.00
Basic EPS
3.15
6.58
2.44
4.51
-1.44
Diluted EPS
3.14
6.56
2.42
4.46
-1.44
Basic Average Shares
80,843.00
81,917.00
82,396.60
82,032.39
74,581.41
Diluted Average Shares
80,957.70
82,216.20
82,914.70
82,792.03
74,581.41
Total Expenses
420,926.00
420,659.00
343,717.00
322,639.00
227,703.00
Net Income from Continuing & Discontinued Operation
254,330.00
539,397.00
200,714.00
369,601.00
-106,829.00
Normalized Income
254,725.76
539,397.00
200,714.00
369,601.00
-106,829.00
Interest Income
9,354.00
14,178.00
9,875.00
2,877.00
3,646.00
Interest Expense
142.00
201.00
510.00
618.00
778.00
Net Interest Income
9,212.00
13,977.00
9,365.00
2,259.00
2,868.00
EBIT
334,959.00
623,215.00
264,613.00
397,439.00
-136,620.00
EBITDA
365,585.00
655,522.00
300,161.00
433,262.00
-104,694.00
Reconciled Cost of Revenue
253,377.00
273,637.00
212,955.00
193,361.00
88,542.00
Reconciled Depreciation
30,626.00
32,307.00
35,548.00
35,823.00
31,926.00
Net Income from Continuing Operation Net Minority Interest
254,330.00
539,397.00
200,714.00
369,601.00
-106,829.00
Total Unusual Items Excluding Goodwill
-521.00
--
--
--
--
Total Unusual Items
-521.00
--
--
--
--
Normalized EBITDA
366,106.00
655,522.00
300,161.00
433,262.00
-104,694.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-125.24
--
--
--
--
12/31/2020 - 10/26/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4162.TWO PharmaEngine, Inc.
95.10
+2.15%
4743.TWO Oneness Biotech Co., Ltd.
79.70
+1.66%
6589.TWO EirGenix Inc.
79.80
+1.01%
4147.TWO TaiMed Biologics Inc.
86.50
+0.35%
6535.TWO Lumosa Therapeutics Co., Ltd.
263.50
-0.57%
6550.TW Polaris Group
43.40
+0.46%
4726.TWO Mycenax Biotech Inc.
40.25
0.00%
4174.TWO OBI Pharma, Inc.
56.90
+1.25%
6733.TWO BioGend Therapeutics Co., Ltd.
33.00
0.00%
6919.TW CALIWAY BIOPHARMACEUTICALS CO L
665.00
+3.74%